A Phase 3 interventional study of rosuvastatin calcium and rosuvastatin calcium in Familial Hypercholesterolaemia, sponsored by AstraZeneca. Completed at 14 sites in 5 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2015-04-07.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands — 5 open to participants now, 7 under way, 4 of them phase 3. Hyperlipoproteinemia Type II · Netherlands.
Among the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, this one is the 8th largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2010, is one of 14 in phase 3, and was the 12th registered.
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →5 of the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Netherlands, United States, Australia and 17 more countries
Ages 6–17
Novartis Pharmaceuticals · Sites in Netherlands, United States, Austria and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in Netherlands, United States, Argentina and 20 more countries
Ages 6–11
Verve Therapeutics, Inc. · Sites in Netherlands, United States, Australia and 3 more countries
Ages 18–70
Novartis Pharmaceuticals · Sites in Netherlands, United States, Argentina and 23 more countries
Ages 2–100
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 17 · Phase 4 1
First in 2000; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 315 is above the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 153 across the 33 interventional studies, 29 across the 2 observational. Of the 28 that completed or were terminated, 15 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 35 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 4 studies filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being carried out to see if the study medication, rosuvastatin, is effective in treating familial hypercholesterolaemia in children and adolescents, and to determine the long term (over 2 years) safety, tolerability and efficacy of the study medication in these patients.
This study will also measure levels of drug in the blood and see how well it is tolerated. This is known as pharmacokinetic (PK) analysis.
At baseline only a small number of patients will participate in a single dose PK phase over 24 hours.
In order to see if this medication works, a control group of healthy siblings will help the researchers to compare certain results.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: rosuvastatin calcium
5 mg, oral, once daily, 24 months
Also known as: Crestor
10 mg, oral, once daily, 24 months
Also known as: Crestor
20 mg, oral, once daily, 24 months
Also known as: Crestor
Percent Change From Baseline in LDL-C
Negative values represent a decrease and positive values represent an increase. In total, 198 patients were treated. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.
Time frame: At Month 3, Month 12 and Month 24
Sexual Maturation by Tanner Staging at Baseline
Tanner stages (I-V) was used to characterize physical development in children and adolescent. The stages was based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. Tanner stage is considered going up when the organs grow bigger.
Time frame: At Baseline
Single Dose PK - Cmax
Serial plasma samples were taken at baseline (Week 0) at: 0.5 hours pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours and on Day 1 at 24 hours after the single 10 mg dosing
Time frame: Serial blood samples over 24 hours.
Percent Change From Baseline in Height
One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.
Time frame: At Month 12 and Month 24
Sexual Maturation by Tanner Staging at Month 12
Tanner stages (I-V) was used to characterize physical development in children and adolescent. The stages was based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. Tanner stage is considered going up when the organs grow bigger.
Time frame: At Baseline
Sexual Maturation by Tanner Staging at Month 24
Tanner stages (I-V) was used to characterize physical development in children and adolescent. The stages was based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. Tanner stage is considered going up when the organs grow bigger.
Time frame: At Baseline
Single Dose PK - Tmax
Serial plasma samples were taken at baseline (Week 0) at: 0.5 hours pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours and on Day 1 at 24 hours after the single 10 mg dosing
Time frame: Serial blood samples over 24 hours
Single Dose PK - AUC(0-24)
Serial plasma samples were taken at baseline (Week 0) at: 0.5 hours pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours and on Day 1 at 24 hours after the single 10 mg dosing
Time frame: Serial blood samples over 24 hours
Percent Change From Baseline in HDL-C, TC, TG, Non-HDL-C, LDL-C/HDL-C, TC/HDL-C, Non HDL C/HDL-C, ApoB, ApoA-1, and ApoB/ApoA-1
One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.
Time frame: At Month 3, Month 12 and Month 24
Change From Baseline in Max and Mean Carotid Intima and Media Wall Thickness (cIMT)
One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.
Time frame: At Month 12 and Month 24
Adverse Events
Number of participants with Various Categories of AE's. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.
Time frame: 2-year study period
Total Duration of Exposure
Total duration of exposure was calculated as \[last dose date of rosuva - first dose date of rosuva + 1 day\]. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.
Time frame: 2-year study period
Overal Treatment Adherence
Overall adherence rate was calculated as the weighted mean of adherence rates of all consecutive visits after baseline, in which the adherence rate between 2 consecutive visits was a percentage of the number of rosuvastatin taken divided by duration of exposure. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.
Time frame: 2-year study period
250 patients with FH were screened. Additionally, 65 healthy siblings (HS) were enrolled. HS refers to healthy subjects that were siblings of either the study participants or other paediatric patients with HeFH that were not participating in the study. HS were enrolled to have assessments of cIMT, but did not participate further.
| Milestone | Rosuvastatin | Healthy Siblings |
|---|---|---|
| Started | 250 | 65 |
| Patients treated | 198 | 0 |
| Completed | 182 | 59 |
| Not completed | 68 | 6 |
| Withdrew: Withdrawal by subject | 7 | 3 |
| Withdrew: Protocol violation | 56 | 0 |
| Withdrew: Provided in crf for specific reasons | 2 | 3 |
| Withdrew: Adverse event | 3 | 0 |
Negative values represent a decrease and positive values represent an increase. In total, 198 patients were treated. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.
| Percentage change | Rosuvastatin |
|---|---|
| LDL-C %Change from Baseline at month 3 | -37.86 ± 14.392 |
| LDL-C %Change from Baseline at month 12 | -43.67 ± 14.896 |
| LDL-C %Change from Baseline at month 24 | -42.88 ± 18.222 |
Tanner stages (I-V) was used to characterize physical development in children and adolescent. The stages was based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. Tanner stage is considered going up when the organs grow bigger.
| Participants | Rosuvastatin |
|---|---|
| Tanner Stage I at Baseline | 81 ± NA |
| Tanner Stage II at Baseline | 32 ± NA |
| Tanner Stage III at Baseline | 18 ± NA |
| Tanner Stage IV at Baseline | 44 ± NA |
| Tanner Stage V at Baseline | 21 ± NA |
| Not Recorded at Baseline | 1 |
Serial plasma samples were taken at baseline (Week 0) at: 0.5 hours pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours and on Day 1 at 24 hours after the single 10 mg dosing
| ng/mL | Rosuvastatin |
|---|---|
| Single Dose PK - Cmax | 3.5717 ± 3.22350 |
One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.
| Percent change | Rosuvastatin |
|---|---|
| HDL-C %Change from Baseline at Month 3 | 5.67 ± 17.445 |
| HDL-C %Change from Baseline at Month 12 | 6.35 ± 16.725 |
| HDL-C %Change from Baseline at Month 24 | 11.73 ± 19.996 |
| TC %Change from Baseline at Month 3 | -29.60 ± 11.433 |
| TC %Change from Baseline at Month 12 | -33.91 ± 12.050 |
| TC %Change from Baseline at Month 24 | -32.03 ± 14.530 |
| Triglycerides %Change from Baseline at Month 3 | -7.95 ± 34.482 |
| Triglycerides %Change from Baseline at Month 12 | -7.85 ± 37.530 |
| Triglycerides %Change from Baseline at Month 24 | -0.12 ± 37.682 |
| non-HDL C %Change from Baseline at Month 3 | -36.35 ± 13.368 |
| non-HDL C %Change from Baseline at Month 12 | -41.66 ± 14.235 |
| non-HDL C %Change from Baseline at Month 24 | -40.40 ± 17.555 |
| LDL-C/HDL-C %Change from Baseline at Month 3 | -39.66 ± 17.381 |
| LDL-C/HDL-C %Change from Baseline at Month 12 | -45.63 ± 17.082 |
| LDL-C/HDL-C %Change from Baseline at Month 24 | -46.95 ± 20.126 |
| TC/HDL-C %Change from Baseline at Month 3 | -31.77 ± 14.874 |
| TC/HDL-C %Change from Baseline at Month 12 | -36.54 ± 14.474 |
| TC/HDL-C %Change from Baseline at Month 24 | -37.39 ± 17.079 |
| Trig/HDL-C %Change from Baseline at Month 3 | -9.05 ± 41.765 |
| Trig/HDL-C %Change from Baseline at Month 12 | -10.50 ± 40.633 |
| Trig/HDL-C %Change from Baseline at Month 24 | -7.12 ± 40.585 |
| non-HDL-C/HDL-C %Change from Baseline at Month 3 | -37.98 ± 17.369 |
| non-HDL-C/HDL-C %Change from Baseline at Month 12 | -43.71 ± 16.731 |
| non-HDL-C/HDL-C %Change from Baseline at Month 24 | -44.74 ± 19.896 |
| ApoA-I %Change from Baseline at Month 3 | 4.77 ± 14.680 |
| ApoA-I %Change from Baseline at Month 12 | 1.41 ± 13.747 |
| ApoA-I %Change from Baseline at Month 24 | 2.34 ± 15.027 |
| ApoB %Change from Baseline at Month 3 | -29.29 ± 12.456 |
| ApoB %Change from Baseline at Month 12 | -35.65 ± 12.424 |
| ApoB %Change from Baseline at Month 24 | -35.72 ± 15.710 |
| ApoB/ApoA-I %Change from Baseline at Month 3 | -31.30 ± 15.524 |
| ApoB/ApoA-I %Change from Baseline at Month 12 | -35.66 ± 13.920 |
| ApoB/ApoA-I %Change from Baseline at Month 24 | -35.94 ± 18.743 |
| hsCRP %Change from Baseline at Month 3 | 512.57 ± 4724.249 |
| hsCRP %Change from Baseline at Month 12 | 42.96 ± 226.954 |
| hsCRP %Change from Baseline at Month 24 | 98.36 ± 565.444 |
One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.
| mm | Rosuvastatin | Healthy Siblings |
|---|---|---|
| Max cIMT Change from Baseline at Month 12 | 0.00626 ± 0.073446 | 0.01707 ± 0.056223 |
| Max cIMT Change from Baseline at Month 24 | 0.00189 ± 0.060864 | 0.01202 ± 0.049102 |
| Mean cIMT Change from Baseline at Month 12 | 0.00282 ± 0.041186 | 0.01564 ± 0.032052 |
| Mean cIMT Change from Baseline at Month 24 | 0.01056 ± 0.040762 | 0.02779 ± 0.031004 |
Number of participants with Various Categories of AE's. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.
| Participant | Rosuvastatin |
|---|---|
| Any AE | 172 |
| AE Leading to Death | 0 |
| AE Leading to Discontinuation | 3 |
| Serious AE | 9 |
| Treatment Related AE | 29 |
| Treatment Related AE Leading to Death | 0 |
| Treatment Related AE Leading to Discontinuation | 3 |
| Treatment Related Serious AE | 0 |
Total duration of exposure was calculated as \[last dose date of rosuva - first dose date of rosuva + 1 day\]. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.
| Days | Rosuvastatin |
|---|---|
| Total Duration of Exposure | 703.5 ± 97.25 |
One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.
| Percent change | Rosuvastatin |
|---|---|
| %Change from Baseline at Month 12 | 3.20 ± 2.023 |
| %Change from Baseline at Month 24 | 5.91 ± 3.968 |
Tanner stages (I-V) was used to characterize physical development in children and adolescent. The stages was based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. Tanner stage is considered going up when the organs grow bigger.
| Participants | Rosuvastatin |
|---|---|
| Tanner Stage I at Month 12 | 61 ± NA |
| Tanner Stage II at Month 12 | 31 ± NA |
| Tanner Stage III at Month 12 | 21 ± NA |
| Tanner Stage IV at Month 12 | 32 ± NA |
| Tanner Stage V at Month 12 | 42 ± NA |
| Not Recorded at Month 12 | 10 |
Tanner stages (I-V) was used to characterize physical development in children and adolescent. The stages was based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. Tanner stage is considered going up when the organs grow bigger.
| Participants | Rosuvastatin |
|---|---|
| Tanner Stage I at Month 24 | 43 ± NA |
| Tanner Stage II at Month 24 | 33 ± NA |
| Tanner Stage III at Month 24 | 23 ± NA |
| Tanner Stage IV at Month 24 | 32 ± NA |
| Tanner Stage V at Month 24 | 64 ± NA |
| Not Recorded at Month 24 | 2 |
Serial plasma samples were taken at baseline (Week 0) at: 0.5 hours pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours and on Day 1 at 24 hours after the single 10 mg dosing
| hr | Rosuvastatin |
|---|---|
| Single Dose PK - Tmax | 2.664 ± 1.8851 |
Serial plasma samples were taken at baseline (Week 0) at: 0.5 hours pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours and on Day 1 at 24 hours after the single 10 mg dosing
| ng*hr/mL | Rosuvastatin |
|---|---|
| Single Dose PK - AUC(0-24) | 27.675 ± 26.6417 |
Overall adherence rate was calculated as the weighted mean of adherence rates of all consecutive visits after baseline, in which the adherence rate between 2 consecutive visits was a percentage of the number of rosuvastatin taken divided by duration of exposure. One patient received 1 dose of study drug but was not included in the efficacy and safety analyses due to a lack of follow-up data.
| Percent of doses | Rosuvastatin |
|---|---|
| Overal Treatment Adherence | 89.6 ± 12.25 |
Collected over Treatment Phase. Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuvastatin | — | 9/197 (4.6%) | 172/197 (87.3%) |
| Event | Rosuvastatin |
|---|---|
| AppendicitisInfections and infestations | 1/197 |
| Urinary retention postoperativeInjury, poisoning and procedural complications | 1/197 |
| Forearm fractureInjury, poisoning and procedural complications | 1/197 |
| Streptococcal toxic shock syndromeInfections and infestations | 1/197 |
| Femur fractureInjury, poisoning and procedural complications | 1/197 |
| Viral pericarditisInfections and infestations | 1/197 |
| Multiple fracturesInjury, poisoning and procedural complications | 1/197 |
| Leg fractureInjury, poisoning and procedural complications | 1/197 |
| EpilepsyNervous system disorders | 1/197 |
| Pectus carinatumCongenital, familial and genetic disorders | 1/197 |
| Event | Rosuvastatin |
|---|---|
| NasopharyngitisInfections and infestations | 88/197 |
| HeadacheNervous system disorders | 46/197 |
| InfluenzaInfections and infestations | 20/197 |
| VomitingGastrointestinal disorders | 19/197 |
| NauseaGastrointestinal disorders | 18/197 |
| Gastroenteritis viralInfections and infestations | 18/197 |
| Influenza like illnessGeneral disorders | 16/197 |
| Abdominal pain upperGastrointestinal disorders | 15/197 |
| Abdominal painGastrointestinal disorders | 13/197 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 13/197 |
Rosuvastatin; All treated patients. Healthy siblings; All patient who started this study
| Age, Continuous(Years) | Rosuvastatin | Healthy Siblings | Total |
|---|---|---|---|
| Years | 11.6 ± 3.33 | 11.5 ± 3.53 | 11.55 ± 3.43 |
| Sex: Female, Male(Participants) | Rosuvastatin | Healthy Siblings | Total |
|---|---|---|---|
| Female | 110 | 32 | 142 |
| Male | 88 | 33 | 121 |
| Race/Ethnicity, Customized(Participants) | Rosuvastatin | Healthy Siblings | Total |
|---|---|---|---|
| Caucasian | 178 | 53 | 231 |
| non-Caucasian | 20 | 12 | 32 |
The record gives a start of Feb 2010, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin
Hyperlipoproteinemia Type II →